Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: Results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages

  Papp, K A ^a   Kaufmann, R ^b   Thaci D ^b   Hu, C ^c   Sutherland, D ^c   Rohane, P ^c  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b GOETHE UNIVERSITY   (Germany)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; PLACEBO;

ABDOMINAL DISTENSION; ADULT; ALCOHOLISM; ARTICLE; BODY SURFACE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; OPPORTUNISTIC INFECTION; PANIC; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; HUMANS; PLACEBOS; PSORIASIS; SEVERITY OF ILLNESS INDEX; THALIDOMIDE;

EID: 84874110064     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04716.x     Document Type: Article

References (24)

1. Kurd SK, Gelfand JM,. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009; 60: 218-224.
2. Augustin M, Reich K, Glaeske G, et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151.
3. Lebwohl M,. Psoriasis. Lancet 2003; 361: 1197-1204.
4. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138.
5. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
6. Sobell JM, Hallas SJ,. Systemic therapies for psoriasis: understanding current and newly emerging therapies. Semin Cutan Med Surg 2003; 22: 187-195.
7. Menter A, Hamilton TK, Toth DP, et al. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. Int J Dermatol 2007; 46: 637-648.
8. Saurat JH, Guerin A, Yu AP, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010; 220: 128-137.
9. Ravindran V, Scott DL, Choy EH,. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008; 67: 855-859.
10. Enbrel (etanercept) [package insert]. Immunex Corporation, Thousand Oaks, CA, 2011.
11. Rheumatrex (methotrexate) [package insert]. DAVA Pharmaceuticals, Inc., Fort Lee, NJ, 2009.
12. Richards HL, Fortune DG, Griffiths CE,. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 370-379.
13. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
14. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
15. Brunasso AM, Puntoni M, Salvini C, et al. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Derm Venereol 2011; 91: 44-49.
16. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159: 842-855.
17. Schafer P,. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83: 1583-1590.
18. Papp K, Cather J, Rosoph L, et al. The efficacy of apremilast, a phosphodiesterase-4 inhibitor, in the treatment of moderate to severe psoriasis: results of a phase 2 randomised study. Lancet 2012; 380: 738-746.
19. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 21 Jun Doi:10.1002/art.34580. [Epub ahead of print].
20. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008; 24: 1529-1538.
21. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
22. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-1199.
23. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-833.
24. Hick J, Feldman SR,. Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol 2007; 57: 972-976.